Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/11/2020 (updated 4/3/2024)
This report describes decedent demographic characteristics and circumstances surrounding overdose deaths during January–June 2019 among 25 jurisdictions participating in CDC’s State Unintentional Drug Overdose Reporting System (SUDORS),† and it highlights the involvement of opioids and stimulants, separately and in combination.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 9/4/2020 (updated 3/29/2024)
The analysis examined syndromic surveillance data from 2018–2019 in 29 states for suspected nonfatal drug and polydrug overdoses treated in emergency departments.
Posted 5/11/2020 (updated 3/28/2024)
The United States is in the midst of an epidemic of prescription opioid overdoses. The amount of opioids prescribed and sold in the US quadrupled since 1999, but the overall amount of pain reported by Americans hasn’t changed. This epidemic is devastating American lives, families, and communities.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 5/25/2022 (updated 3/27/2024)
CDC’s Division of Overdose Prevention has developed an interactive data visualization tool, the DOSE Dashboard, which displays current nonfatal overdose data. The nonfatal drug overdose data on this dashboard are from CDC’s Drug Overdose Surveillance and Epidemiology (DOSE) system, which captures electronic health record information in syndromic surveillance data systems. DOSE data can be used to compare monthly and annual trends in nonfatal drug overdose-related ED visits by drug type (i.e., all drugs, all opioids, heroin, and all stimulants), state, and sex and age group.
Posted 11/24/2021 (updated 3/26/2024)
This webinar will provide participants with an understanding of the role of the medical examiners and coroners in the surveillance of drug overdose deaths, as well as the current efforts to strengthen the death investigation system. The webinar will also cover an overview of the overdose fatality review process and tools available for implementation.